The pitch begins with a patient, not a platform. Imagine a 62-year-old with stable coronary artery disease, already on a high-intensity statin and a PCSK9 inhibitor, whose LDL is finally under control but whose arterial plaque is still there, still inflamed, still the thing most likely to kill them. That patient is the one Vertical Longevity Pharma is building for, and the company's bet is that the next move in cardiovascular medicine is not another lipid drug but an immunotherapy that teaches the body to clear the senescent cells embedded in the plaque itself [Company site].
The Irvine, California company was founded in 2024 by David Scieszka and is still preclinical, working on what it calls a senolytic vaccine: a virus-like particle, or VLP, engineered to mimic a virus without any infectious capacity and to provoke an immune response against senescent cells [Netcapital]. The initial indication is atherosclerosis. The longer arc is a platform that could be pointed at other diseases of aging [Netcapital].
The wager on senescent cells
Senolytics, drugs that selectively kill senescent cells, have been one of the most watched and most humbling categories in aging biology. Unity Biotechnology, the field's most prominent public company, has spent years cycling through indications. Calico, Juvenescence, Dorian Therapeutics, Oisín Biotechnologies, Cleara Biotech and Numeric Biotech are all working adjacent angles. Vertical Longevity's wager is that an active immunization, rather than a small molecule dosed repeatedly, is the right shape of intervention for a chronic, slow-burning disease like atherosclerosis [Company site].
The preclinical readout the company points to is narrow but on-target for the thesis. In mouse studies, the approach has shown plaque prevention and restoration of cardiac function, and the next planned step is efficacy work in human-relevant primates [Kingscrowd, 2025] [Company site]. Mouse-to-primate is the bridge where most cardiovascular programs either earn the right to file an IND or quietly fold.
Why a vaccine, why now
Atherosclerosis remains the leading cause of death worldwide, and the field has spent two decades proving that lowering LDL cholesterol, even very aggressively, leaves a large residual risk untouched [F6S]. That residual risk is where the inflammation-and-senescence hypothesis lives. A VLP-based shot that durably trains the immune system to recognize and remove senescent vascular cells would, if it worked, address a mechanism that statins and PCSK9 inhibitors do not [Netcapital].
Three things make the timing rational, even if the science is early:
- A mechanism the field now takes seriously. Cellular senescence has moved from a curiosity to a named driver of vascular disease, and multiple well-funded companies are competing to drug it [Netcapital].
- A delivery format with regulatory precedent. VLPs are the backbone of approved vaccines for HPV and hepatitis B, which gives the FDA a familiar framework to evaluate manufacturing and safety, even if the senolytic application is novel [Netcapital].
- A capital base willing to fund aging biology again. Sila B Health Ventures, a 2024-vintage boutique focused on chronic diseases of aging, is named as an investor, alongside angel commitments and a tech transfer office supporting IND-enabling work [F6S] [Netcapital].
Where it could break
None of that makes the program safe. The senolytic field's track record is the most honest counterfactual on offer, and a vaccine raises a specific worry that a small molecule does not: a sustained, antibody-mediated response against a cell population the body sometimes needs. Senescent cells play roles in wound healing and tumor suppression, and a durable immunization is harder to switch off than a daily pill. Regulators will want a long safety tail before any cardiovascular efficacy trial of meaningful size.
| Company | Approach | Stage signal |
|---|---|---|
| Vertical Longevity Pharma | VLP senolytic vaccine, atherosclerosis-first | Preclinical, primate studies planned [Company site] |
| Unity Biotechnology | Small-molecule senolytics | Clinical, multiple indications attempted |
| Cleara Biotech | Senolytic peptides | Preclinical / early clinical |
| Dorian Therapeutics | Small-molecule senolytics | Preclinical |
| Oisín Biotechnologies | Gene-therapy senolytic | Preclinical |
Funding is also early. The company has not disclosed a round size, and a Netcapital community offering is part of the current capital stack [Wixdom]. IND-enabling toxicology, GMP manufacturing of a VLP, and a primate efficacy package are each multi-million-dollar line items on their own.
The patient on the other end
The disease this program is aimed at is atherosclerotic cardiovascular disease, and the patient population is the tens of millions of adults living with established coronary or carotid plaque, the ones whose risk does not zero out even after their lipid panel looks textbook. For that patient today, the standard of care is layered and lifelong: a high-intensity statin, often ezetimibe, a PCSK9 inhibitor or inclisiran for those who need deeper LDL reduction, antiplatelet therapy after an event, blood pressure control, and, when anatomy demands it, a stent or bypass. It works, in the sense that it reduces events. It does not clear the plaque that is already there. That gap, between controlling the inputs and removing the lesion, is the one Vertical Longevity is asking primates, and eventually the FDA, to let it try to close [Company site].
Sources
- [Netcapital] Learn about Vertical Longevity Pharma | https://netcapital.com/companies/vertical-longevity
- [Company site] Vertical Longevity Pharma | https://vertical-longevity-pharma.com/
- [Kingscrowd, 2025] Vertical Longevity Pharma on NetCapital 2025 | https://kingscrowd.com/vertical-longevity-pharma-on-netcapital-2025/
- [F6S] Vertical Longevity Pharmaceuticals | https://www.f6s.com/company/vertical-longevity-pharmaceuticals
- [Wixdom] Vertical Longevity Pharma offering | https://www.wixdom.io/app/offerings/netcapital_vertical_longevity_0